MALVERN PA., (August 22, 2024) — HMP Global’s 2024 Lymphoma, Leukemia & Myeloma Congress (LL&M) is partnering with the Clinical Research Alliance (CRA), strengthening its position as the premier educational conference dedicated to industry-leading hematologic research and clinical case studies. 

 

LL&M will be held October 16-19 in New York City, bringing together experts from around the globe to review the latest clinical evidence, debate optimal treatment strategies, and share best practices with one of the largest live audiences in the field. At LL&M, the world’s leading educators discuss the latest scientific advances and equip attendees with tools to advance their clinical practice, improve patient’s quality of life, and create better patient outcomes.

 

CRA is comprised of dedicated physicians, nurses and healthcare professionals who are committed to providing patients with the opportunity to participate in cutting edge clinical trials testing experimental cancer treatments in their local communities. CRA has a community-oriented mindset and is focused on helping diverse and underserved communities.  CRA assists local physicians in providing high quality clinical trial services on the front line of disease. It has participated in nearly 200 clinical trials delivering access to thousands of patients.  Because of CRA’s reputation for quality, integrity and prompt and efficient study start up, CRA has recently been named first clinical research site open both nationally and worldwide for many clinical trials. 
 

“At CRA, we envision a future where healthcare disparities are eliminated, granting equal access to cutting-edge treatments and research opportunities for individuals regardless of their background or the communities they live in” said Dr. James D’Olimpio, CMO and Principal Investigator  of CRA We are grateful to Dr. Morton Coleman, a founder and highly respected mentor of CRA and founder of the Congress, for his support and invitation to attend the Congress. We are proud to partner with LL&M as we work together to create a healthier and more inclusive society.”
 

“The partnership with CRA was a natural fit for us,” said Jennifer Browne, Associate Vice President, Educational Programming, HMP Education. “Both organizations are working to advance the science and clinical trials that will improve care and outcomes for patients with blood cancers. The work our organizations do is vital, and together we can make an even bigger impact.”

​

The Congress attracts more than 1,000 delegates each year for an educational program led by more than 60 renowned faculty experts. LL&M is open to hematologists, medical oncologists, physicians, physician assistants, physicians in training, oncology nurses, nurse practitioners, and pharmacists. 

 

For more information or to register for LL&M, visit hmpglobalevents.com/llmcongress.

 

ABOUT HMP GLOBAL   

HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit hmpglobal.com.

 

ABOUT CLINICAL RESEARCH ALLIANCE

CRA enables access to clinical trials and research making it easier for patients and providers to participate in accelerating the development of new and innovative cancer treatments that impact patient lives. By providing state-of-the-art clinical research in a community setting, CRA also makes clinical research more accessible to underserved populations enables faster enrollment, better retention and a patient population that is representative of real-world populations. For more information, visit clincialresearchalliance.org.  CRA is a wholly owned subsidiary of Optimus Healthcare Services, Inc.  (OTC PINK:OHCS),